MIODx, a San Jose, CA-based developer of cancer biomarkers, closed a $1.5m seed funding round.
Backers were not disclosed.
The company will use the funds to complete the clinical utility study for its VerifyDx Prostate Cancer test and begin commercialization of the test.
Led by Sean Givens, COO and co-founder, and Allen Northrup, CEO, MIODx is advancing VerifyDx, an oncology testing platform that utilizes a multiplexed assay to interrogate expression levels of biomarkers implicated in cancer aggressiveness. Started with prostate cancer, the company plans to launch additional tests including colon, lung, and kidney. MIODx is also developing, and has IP surrounding, the sequencing of T cell repertoires.